Psoriasis, An inflammatory condition associated with oxidative stress

Psoriasis, An inflammatory condition associated with oxidative stress

Background: Psoriasis is a chronic inflammatory skin disease characterized by pathological skin lesions due to various exogenous and endogenous factors. Oxidative stress can be one of the causes for the occurrence of psoriasis as well as significant contributor to its progression. Skin exposure to a...

Full description

Bibliographic Details
Main Authors:	Swati Pal, Sumit Sen, Indrajit Nath, Arun Kumar, Utpal Kumar Biswas
Format:	Article
Language:	English
Published:	Manipal College of Medical Sciences, Pokhara 2021-04-01
Series:	Asian Journal of Medical Sciences
Subjects:	psoriasis oxidative stress malondialdehyde (mda) nitric oxide end product (nox) hs-crp pasi (psoriasis area and severity index)
Online Access:	https://www.nepjol.info/index.php/AJMS/article/view/33343

Similar Items

Study of serum Ceruloplasmin, Malondialdehyde (MDA) and hs-CRP as biomarkers of severity in Psoriasis
by: 1. K Prashanth, Assistant Professor, Department of Biochemistry, Rajiv Gandhi Institute of Medical Sciences [RIMS], Adilabad, Telangana State, India. 2. MohdInayatulla Khan, Assistant Professor, Department of Physiology, Rajiv Gandhi Institute of Medical Sciences [RIMS], Adilabad, Telangana State, India.
Published: (2020-12-01)

The Role of IL-18, TNF-α and hs-CRP among Iraqi psoriatic Patients and their Correlation with Disease Severity
by: Suzan Yousif Jasim
Published: (2018-03-01)

Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study
by: Giovanni Fiorillo, et al.
Published: (2024-02-01)

PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis
by: A. A. Kubanov, et al.
Published: (2017-08-01)

Pengaruh Suplementasi Vitamin D Terhadap Perubahan Skor Psoriasis Area and Severity Index (PASI) Pada Pasien Psoriasis: Studi Kasus Dengan Pendekatan Berbasis Bukti
by: Anni Rahmawati, et al.
Published: (2024-03-01)

Role of GDF-15 as an inflammatory marker in patients with psoriasis vulgaris
by: Mustafa Kaan Taşolar, et al.
Published: (2021-12-01)

Plasma homocysteine levels in patients with Psoriasis
by: Mousumi Das
Published: (2017-08-01)

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
by: K. B. Gordon, et al.
Published: (2022-01-01)

PASI and PQOL-12 score in psoriasis : Is there any correlation?
by: Vikas Shankar, et al.
Published: (2011-01-01)

Myeloperoxidase Inhibition Ameliorates Plaque Psoriasis in Mice
by: Savannah D. Neu, et al.
Published: (2021-08-01)

Relationship of Staphylococcal Aureus Colonization with Severity of Psoriasis Vulgaris Disease According to PASI Score
by: A. Darjani, et al.
Published: (2014-01-01)

Evaluation Of Neopterin Level And Disease Severity In Patients With Psoriasis Vulgaris Treated With Narrowband UVB
by: Eisa Mohamed Hegazy, et al.
Published: (2023-07-01)

A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology
by: Tadas Raudonis, et al.
Published: (2020-06-01)

Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
by: Mark Lebwohl, et al.
Published: (2022-05-01)

Evaluation of therapeutic response of methotrexate and calcipotriol combination compared with methotrexate alone in plaque psoriasis
by: Deepthi Vasanthada, et al.
Published: (2014-04-01)

An Observational Study of 147 Psoriasis Patients: Overweightness and Obesity as a Significant Clinical Factors Correlated with Psoriasis
by: Anna Czarnecka, et al.
Published: (2023-11-01)

Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab
by: Jeanette Halskou Hesselvig, et al.
Published: (2017-12-01)

Facial psoriasis in a mask-like distribution
by: Cameron M.B. Zachary, MS, et al.
Published: (2021-01-01)

Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis
by: sana imran, et al.
Published: (2014-08-01)

Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis
by: sana imran, et al.
Published: (2014-08-01)

Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis
by: Sana Imran, et al.
Published: (2014-08-01)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
by: Marco Galluzzo, et al.
Published: (2020-07-01)

Body mass index, disease duration and tumor necrosis factor inhibitor history predict reduced ustekinumab response in Chinese psoriasis patients: A real-world study
by: Xue Xu, et al.
Published: (2021-01-01)

Psoriasis can markedly impair the quality of life of patients irrespective of severity: Results of a hospital-based cross-sectional study
by: Ajith Vettuparambil, et al.
Published: (2016-01-01)

Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers
by: Tzu-Chang Wang, et al.
Published: (2015-03-01)

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
by: Boni Elewski, et al.
Published: (2020-11-01)

Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis
by: Hengge UR, et al.
Published: (2017-06-01)

The Association of Serum Lipid Profiles and Dietary Intakes of Vitamin E and Fiber with Psoriasis Severity
by: Mohammad Javad Yazdanpanah, et al.
Published: (2021-09-01)

Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment
by: Ali Al Raddadi, et al.
Published: (2016-01-01)

Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
by: Steven R. Feldman, et al.
Published: (2022-04-01)

Effect of Disease Severity on the Quality of Life and Sense of Stigmatization in Psoriatics
by: Kowalewska B, et al.
Published: (2021-02-01)

The Serum Levels of Malondialdehyde, Vitamin E and Erythrocyte Catalase Activity in Psoriasis Patients
by: Vijaykumar M. Pujari, et al.
Published: (2014-11-01)

Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
by: Sascha Gerdes, et al.
Published: (2020-07-01)

The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis
by: Jenny M. Norlin, et al.
Published: (2023-11-01)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01)

Associations between body mass index and severity of psoriasis
by: Sobhan M, et al.
Published: (2017-11-01)

Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis
by: Gil Yosipovitch, et al.
Published: (2019-07-01)

Alteration in lipid profile and lipid indices as cardiometabolic risk markers in psoriasis
by: Neela Mannangi, et al.
Published: (2020-01-01)

Psoriazisin klinik şiddeti ile histopatolojik bulgular arasında ilişki var mıdır? klinikopatolojik bir çalışma
by: Figen ASLAN
Published: (2019-06-01)

CD19+ B cell subsets in the peripheral blood and skin lesions of psoriasis patients and their correlations with disease severity
by: J. Lu, et al.
Published: (2016-01-01)